197 related articles for article (PubMed ID: 34789470)
1. The Improving Risk Informed HPV Screening (IRIS) Study: Design and Baseline Characteristics.
Gage JC; Raine-Bennett T; Schiffman M; Clarke MA; Cheung LC; Poitras NE; Varnado NE; Katki HA; Castle PE; Befano B; Chandra M; Rydzak G; Lorey T; Wentzensen N
Cancer Epidemiol Biomarkers Prev; 2022 Feb; 31(2):486-492. PubMed ID: 34789470
[TBL] [Abstract][Full Text] [Related]
2. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
3. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
[TBL] [Abstract][Full Text] [Related]
4. Clinical Evaluation of Human Papillomavirus Screening With p16/Ki-67 Dual Stain Triage in a Large Organized Cervical Cancer Screening Program.
Wentzensen N; Clarke MA; Bremer R; Poitras N; Tokugawa D; Goldhoff PE; Castle PE; Schiffman M; Kingery JD; Grewal KK; Locke A; Kinney W; Lorey TS
JAMA Intern Med; 2019 Jul; 179(7):881-888. PubMed ID: 31081870
[TBL] [Abstract][Full Text] [Related]
5. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
[TBL] [Abstract][Full Text] [Related]
6. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
7. Comparison of human papillomavirus genotyping and cytology triage, COMPACT Study: Design, methods and baseline results in 14 642 women.
Aoyama-Kikawa S; Fujita H; Hanley SJB; Kasamo M; Kikuchi K; Torigoe T; Matsuno Y; Tamakoshi A; Sasaki T; Matsuura M; Kato Y; Dong P; Watari H; Saito T; Sengoku K; Sakuragi N
Cancer Sci; 2018 Jun; 109(6):2003-2012. PubMed ID: 29660849
[TBL] [Abstract][Full Text] [Related]
8. The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1-year follow-up phase.
Safaeian M; Wright TC; Stoler MH; Ranger-Moore J; Rehm S; Aslam S; Fang Q; Volkir P; Ridder R
Am J Obstet Gynecol; 2021 Sep; 225(3):278.e1-278.e16. PubMed ID: 33852886
[TBL] [Abstract][Full Text] [Related]
9. Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial -- the HPV FOCAL Study.
Ogilvie GS; Krajden M; van Niekerk DJ; Martin RE; Ehlen TG; Ceballos K; Smith LW; Kan L; Cook DA; Peacock S; Stuart GC; Franco EL; Coldman AJ
Br J Cancer; 2012 Dec; 107(12):1917-24. PubMed ID: 23169286
[TBL] [Abstract][Full Text] [Related]
10. Approaches to triage optimization in HPV primary screening: Extended genotyping and p16/Ki-67 dual-stained cytology-Retrospective insights from ATHENA.
Stoler MH; Baker E; Boyle S; Aslam S; Ridder R; Huh WK; Wright TC
Int J Cancer; 2020 May; 146(9):2599-2607. PubMed ID: 31490545
[TBL] [Abstract][Full Text] [Related]
11. Effect of Sequential Rounds of Cervical Cancer Screening on Management of HPV-positive Women: A 15-year Population-based Cohort Study from China.
Xu XQ; Rezhake R; Hu SY; Chen F; Zhang X; Pan QJ; Zhang WH; Ma JF; Qiao YL; Zhao FH; Cruickshank M
Cancer Prev Res (Phila); 2021 Mar; 14(3):363-372. PubMed ID: 33303694
[TBL] [Abstract][Full Text] [Related]
12. Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women.
Clarke MA; Cheung LC; Castle PE; Schiffman M; Tokugawa D; Poitras N; Lorey T; Kinney W; Wentzensen N
JAMA Oncol; 2019 Feb; 5(2):181-186. PubMed ID: 30325982
[TBL] [Abstract][Full Text] [Related]
13. Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain.
Ibáñez R; Moreno-Crespi J; Sardà M; Autonell J; Fibla M; Gutiérrez C; Lloveras B; Alejo M; Català I; Alameda F; Casas M; Bosch FX; de Sanjosé S
BMC Infect Dis; 2012 Jan; 12():25. PubMed ID: 22280073
[TBL] [Abstract][Full Text] [Related]
14. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
Gilham C; Sargent A; Kitchener HC; Peto J
Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
[TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
[TBL] [Abstract][Full Text] [Related]
16. The impact of age and high-risk human papillomavirus (hrHPV) status on the prevalence of high-grade cervical intraepithelial neoplasia (CIN2+) in women with persistent hrHPV-positive, cytology-negative screening samples: a prospective cohort study.
Tidy JA; Lyon R; Ellis K; Macdonald M; Palmer JE
BJOG; 2020 Sep; 127(10):1260-1267. PubMed ID: 32279427
[TBL] [Abstract][Full Text] [Related]
17. Five-Year Cervical (Pre)Cancer Risk of Women Screened by HPV and Cytology Testing.
Uijterwaal MH; Polman NJ; Van Kemenade FJ; Van Den Haselkamp S; Witte BI; Rijkaart D; Berkhof J; Snijders PJ; Meijer CJ
Cancer Prev Res (Phila); 2015 Jun; 8(6):502-8. PubMed ID: 25776933
[TBL] [Abstract][Full Text] [Related]
18. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
[TBL] [Abstract][Full Text] [Related]
19. Cervical cancer screening by high risk HPV testing in routine practice: results at one year recall of high risk HPV-positive and cytology-negative women.
Del Mistro A; Frayle H; Ferro A; Callegaro S; Del Sole A; Stomeo A; Cirillo E; Fedato C; Pagni S; Barzon L; Zorzi M;
J Med Screen; 2014 Mar; 21(1):30-7. PubMed ID: 24488593
[TBL] [Abstract][Full Text] [Related]
20. Primary HPV screening for cervical cancer: Results after two screening rounds in a regional screening program in Finland.
Veijalainen O; Kares S; Kotaniemi-Talonen L; Kujala P; Vuento R; Luukkaala T; Kholová I; Mäenpää J
Acta Obstet Gynecol Scand; 2021 Mar; 100(3):403-409. PubMed ID: 33037625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
